Thank you for researching this, indeed we have to dig into semantics to understand where BLA filing stands at this point.
The final module will be filed during January, and Mesoblast will request an expedited FDA review of the BLA under the product candidate’s existing Fast Track designation. If approved, remestemcel-L is planned to be launched in the US in 2020.
The use of “will” instead of the conditional makes it plain to me that this solely depends at this stage on MSB. Of course, “Shall” would have shown more certainty.
The conditional in the last sentence refers to the Fast Track designation approval.
Hence, the filing of the last module appears to be a matter of form -MSB did not inform the market when previous modules were filed- more than substance while fast track approval is crucial or in other words “material”.
Of course we expect as shareholders a straightforward announcement at each and every step. However in this case maybe a surprise announcement of Fast Track approval would be more appropriate for the SP.
- Forums
- ASX - By Stock
- MSB
- MSB Trading - 2020
MSB Trading - 2020, page-1509
-
- There are more pages in this discussion • 21,652 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B |
Open | High | Low | Value | Volume |
95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 72752 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 205100 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 1.005 |
5 | 57985 | 1.000 |
1 | 50000 | 0.995 |
2 | 20525 | 0.990 |
1 | 10000 | 0.985 |
Price($) | Vol. | No. |
---|---|---|
1.035 | 190122 | 7 |
1.045 | 39714 | 5 |
1.050 | 21696 | 6 |
1.060 | 9750 | 2 |
1.065 | 5780 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online